Cargando…
Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy
Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with sympto...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772215/ https://www.ncbi.nlm.nih.gov/pubmed/33392242 http://dx.doi.org/10.3389/fsurg.2020.554382 |
_version_ | 1783629829737807872 |
---|---|
author | Silverman, Lara Ionescu Heaton, Will Farhang, Niloofar Saxon, Lindsey Hart Dulatova, Galina Rodriguez-Granrose, Daniel Flanagan, Flagg Foley, Kevin T. |
author_facet | Silverman, Lara Ionescu Heaton, Will Farhang, Niloofar Saxon, Lindsey Hart Dulatova, Galina Rodriguez-Granrose, Daniel Flanagan, Flagg Foley, Kevin T. |
author_sort | Silverman, Lara Ionescu |
collection | PubMed |
description | Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with symptomatic DD are limited and are often unsuccessful, so many patients turn to prescription opioids for pain management in a time when opioid usage, addiction, and drug-related deaths are at an all-time high. In this paper, we discuss the etiology of lumbar DD and currently available treatments, as well as the potential for cell therapy to offer a biologic, non-opioid alternative to patients suffering from the condition. Finally, we present an overview of an investigational cell therapy called IDCT (Injectable Discogenic Cell Therapy), which is currently under evaluation in multiple double-blind clinical trials overseen by major regulatory agencies. The active ingredient in IDCT is a novel allogeneic cell population known as Discogenic Cells. These cells, which are derived from intervertebral disc tissue, have been shown to possess both regenerative and immunomodulatory properties. Cell therapies have unique properties that may ultimately lead to decreased pain and improved function, as well as curb the numbers of patients pursuing opioids. Their efficacy is best assessed in rigorous double-blinded and placebo-controlled clinical studies. |
format | Online Article Text |
id | pubmed-7772215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77722152020-12-31 Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy Silverman, Lara Ionescu Heaton, Will Farhang, Niloofar Saxon, Lindsey Hart Dulatova, Galina Rodriguez-Granrose, Daniel Flanagan, Flagg Foley, Kevin T. Front Surg Surgery Low back pain (LBP) is a serious medical condition that affects a large percentage of the population worldwide. One cause of LBP is disc degeneration (DD), which is characterized by progressive breakdown of the disc and an inflamed disc environment. Current treatment options for patients with symptomatic DD are limited and are often unsuccessful, so many patients turn to prescription opioids for pain management in a time when opioid usage, addiction, and drug-related deaths are at an all-time high. In this paper, we discuss the etiology of lumbar DD and currently available treatments, as well as the potential for cell therapy to offer a biologic, non-opioid alternative to patients suffering from the condition. Finally, we present an overview of an investigational cell therapy called IDCT (Injectable Discogenic Cell Therapy), which is currently under evaluation in multiple double-blind clinical trials overseen by major regulatory agencies. The active ingredient in IDCT is a novel allogeneic cell population known as Discogenic Cells. These cells, which are derived from intervertebral disc tissue, have been shown to possess both regenerative and immunomodulatory properties. Cell therapies have unique properties that may ultimately lead to decreased pain and improved function, as well as curb the numbers of patients pursuing opioids. Their efficacy is best assessed in rigorous double-blinded and placebo-controlled clinical studies. Frontiers Media S.A. 2020-12-16 /pmc/articles/PMC7772215/ /pubmed/33392242 http://dx.doi.org/10.3389/fsurg.2020.554382 Text en Copyright © 2020 Silverman, Heaton, Farhang, Saxon, Dulatova, Rodriguez-Granrose, Flanagan and Foley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Silverman, Lara Ionescu Heaton, Will Farhang, Niloofar Saxon, Lindsey Hart Dulatova, Galina Rodriguez-Granrose, Daniel Flanagan, Flagg Foley, Kevin T. Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title | Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title_full | Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title_fullStr | Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title_full_unstemmed | Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title_short | Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy |
title_sort | perspectives on the treatment of lumbar disc degeneration: the value proposition for a cell-based therapy, immunomodulatory properties of discogenic cells and the associated clinical evaluation strategy |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772215/ https://www.ncbi.nlm.nih.gov/pubmed/33392242 http://dx.doi.org/10.3389/fsurg.2020.554382 |
work_keys_str_mv | AT silvermanlaraionescu perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT heatonwill perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT farhangniloofar perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT saxonlindseyhart perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT dulatovagalina perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT rodriguezgranrosedaniel perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT flanaganflagg perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy AT foleykevint perspectivesonthetreatmentoflumbardiscdegenerationthevaluepropositionforacellbasedtherapyimmunomodulatorypropertiesofdiscogeniccellsandtheassociatedclinicalevaluationstrategy |